Nano-formulated CUR (SinaCurcumin®) which exhibited a significantly higher bioavailability for oral consumption was demonstrated to suppress breast cancer cells via inhibiting the expression of cyclinD1 (Hosseini et al., 2019). Here, CCND1 is linked to breast carcinoma.